Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America

ConclusionsPazopanib was used for first-line mRCC treatment in a clinically diverse patient population across Latin America. Real-world PFS and tolerability were similar to clinical studies of pazopanib.FundingNovartis Pharmaceuticals Corporation, Inc.

http://link.springer.com/10.1007/s12325-019-01109-y

Source: Advances in Therapy - October 18, 2019 Category: Drugs & Pharmacology Source Type: research